At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
DFTX Definium Therapeutics
Market Closed 11-06 16:00:00 EST
33.27
+2.91
+9.58%
盘后33.42
+0.15+0.45%
19:43 EST
High33.42Low30.91Vol1.28M
Open31.23D1 Closing30.36Amplitude8.25%
Mkt Cap4.47BTradable Cap4.32BTotal Shares134.37M
T/O41.75MT/O Rate0.98%Tradable Shares129.97M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Earning Preview: Definium Therapeutics this quarter’s revenue is expected to increase by 0%, and institutional views are bullish
Earnings Agent  ·  11-02
Earning Preview: Definium Therapeutics this quarter’s revenue is expected to increase by 0%, and institutional views are bullish
Why Definium Therapeutics Stock Is Up 9.6% And What's Next
Simply Wall St.  ·  11-07 19:29
Why Definium Therapeutics Stock Is Up 9.6% And What's Next
Definium Therapeutics presents Phase 3 data for DT120 ODT at NEI Fall Congress
TIPRANKS  ·  11-04
Definium Therapeutics presents Phase 3 data for DT120 ODT at NEI Fall Congress
Definium Therapeutics Reports Positive Phase 3 Results for DT120 in Generalized Anxiety Disorder
Reuters  ·  11-04
Definium Therapeutics Reports Positive Phase 3 Results for DT120 in Generalized Anxiety Disorder
Definium Therapeutics to Participate in Four Healthcare Investor Conferences
Reuters  ·  11-03
Definium Therapeutics to Participate in Four Healthcare Investor Conferences
Psychedelic Drug Developers Fall After Usona Submits Depressive Drug Application
Reuters  ·  11-03
Psychedelic Drug Developers Fall After Usona Submits Depressive Drug Application
Press Release: Definium Therapeutics to Report Third Quarter 2026 Financial Results on November 9, 2026
Dow Jones  ·  10-30
Press Release: Definium Therapeutics to Report Third Quarter 2026 Financial Results on November 9, 2026
Definium Therapeutics Schedules Third-Quarter Results Webcast
Reuters  ·  10-30
Definium Therapeutics Schedules Third-Quarter Results Webcast
Definium Therapeutics Grants Options for 93,320 Shares to Six New Employees
Reuters  ·  10-27
Definium Therapeutics Grants Options for 93,320 Shares to Six New Employees
Definium Therapeutics Investors Remain Concerned Over Psychedelics' Commercial Scalability, RBC Says
MT Newswires Live  ·  10-19
Definium Therapeutics Investors Remain Concerned Over Psychedelics' Commercial Scalability, RBC Says
Definium Therapeutics Issues Inducement Stock Options for 45,940 Shares to New Hires
Reuters  ·  10-14
Definium Therapeutics Issues Inducement Stock Options for 45,940 Shares to New Hires
Definium Therapeutics Initiated at Overweight by JP Morgan
Dow Jones  ·  10-10
Definium Therapeutics Initiated at Overweight by JP Morgan
U.S. Stocks on the MOVE-SpaceX, Humana, Delta Air Lines
Reuters  ·  10-09
U.S. Stocks on the MOVE-SpaceX, Humana, Delta Air Lines
JPMorgan Initiates Coverage on Definium Therapeutics With Overweight Rating, $84 Price Target
MT Newswires Live  ·  10-09
JPMorgan Initiates Coverage on Definium Therapeutics With Overweight Rating, $84 Price Target
Definium up as J.P.Morgan Starts with 'overweight' Rating on LSD-Based Therapy
Reuters  ·  10-09
Definium up as J.P.Morgan Starts with 'overweight' Rating on LSD-Based Therapy
Definium Therapeutics Shares up 4% Premarket After JP Morgan Initiates Coverage with Overweight Rating
THOMSON REUTERS  ·  10-09
Definium Therapeutics Shares up 4% Premarket After JP Morgan Initiates Coverage with Overweight Rating
Definium Therapeutics Inc : JP Morgan Initiates Coverage with Overweight Rating; Target Price $84
THOMSON REUTERS  ·  10-09
Definium Therapeutics Inc : JP Morgan Initiates Coverage with Overweight Rating; Target Price $84
Definium Therapeutics Currently Down Eight Consecutive Days, on Pace for Longest Losing Streak Since January 2024
Dow Jones  ·  10-09
Definium Therapeutics Currently Down Eight Consecutive Days, on Pace for Longest Losing Streak Since January 2024
Analysts’ Top Healthcare Picks: ArriVent BioPharma, Inc. (AVBP), Definium Therapeutics (DFTX)
TIPRANKS  ·  10-07
Analysts’ Top Healthcare Picks: ArriVent BioPharma, Inc. (AVBP), Definium Therapeutics (DFTX)
Definium Therapeutics Issues Inducement Stock Options for 334,810 Shares to New Hires
Reuters  ·  09-29
Definium Therapeutics Issues Inducement Stock Options for 334,810 Shares to New Hires

Introduction

Company Name.
Definium Therapeutics
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine for the treatment of core symptoms of autism spectrum disorder. The company also develops MM-110, an a3ß4 nicotinic cholinergic receptor antagonist that has completed phase 1 for the treatment of opioid withdrawal. The company is headquartered in New York, New York.
Issue price:
--